Amphastar Pharmaceuticals (NASDAQ: AMPH) is one of 115 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Amphastar Pharmaceuticals to related companies based on the strength of its risk, institutional ownership, dividends, valuation, profitability, analyst recommendations and earnings.
This table compares Amphastar Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Amphastar Pharmaceuticals Competitors||-2,882.43%||-67.86%||-8.82%|
Institutional & Insider Ownership
44.3% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 43.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 11.1% of Amphastar Pharmaceuticals shares are owned by company insiders. Comparatively, 11.8% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Volatility & Risk
Amphastar Pharmaceuticals has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals’ competitors have a beta of 0.90, indicating that their average share price is 10% less volatile than the S&P 500.
This is a summary of recent ratings for Amphastar Pharmaceuticals and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Amphastar Pharmaceuticals Competitors||816||3669||6686||180||2.55|
Amphastar Pharmaceuticals currently has a consensus target price of $20.17, indicating a potential upside of 8.02%. As a group, “Pharmaceuticals” companies have a potential upside of 22.35%. Given Amphastar Pharmaceuticals’ competitors higher probable upside, analysts plainly believe Amphastar Pharmaceuticals has less favorable growth aspects than its competitors.
Valuation and Earnings
This table compares Amphastar Pharmaceuticals and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Amphastar Pharmaceuticals||$249.62 million||$17.41 million||233.40|
|Amphastar Pharmaceuticals Competitors||$8.17 billion||$2.69 billion||-0.32|
Amphastar Pharmaceuticals’ competitors have higher revenue and earnings than Amphastar Pharmaceuticals. Amphastar Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Amphastar Pharmaceuticals beats its competitors on 8 of the 13 factors compared.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company also manufactures and sells insulin API. As of December 31, 2016, the Company manufactured and sold 19 products. As of December 31, 2016, the Company developed a portfolio of 15 generic abbreviated new drug applications (ANDAs) three generic biosimilar product candidates and six injectable and inhalation product candidates.
Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.